Quince Therapeutics Acquires Orphai Therapeutics

Why It Matters

The acquisition expands Quince’s rare‑disease portfolio and provides significant capital to fast‑track LAM‑001, potentially addressing unmet needs in pulmonary disorders and strengthening Quince’s market position.

Key Takeaways

• Quince acquires Orphai, adding inhaled rapamycin LAM-001 to pipeline
• LAM-001 targets rare pulmonary diseases via mTOR inhibition
• Deal includes up to $187 million private placement for pulmonary program
• Acquisition expands Quince's rare‑disease portfolio and market reach
• Cooley led M&A, IP, tax, and cyber‑privacy advisory for Orphai

Pulse Analysis

Quince Therapeutics’ purchase of Orphai Therapeutics marks a strategic move into the niche of inhaled mTOR inhibition for rare lung conditions. By integrating LAM‑001, an inhaled formulation of rapamycin, Quince gains a differentiated asset that could address diseases such as lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis—areas with limited treatment options and high unmet medical need. The $187 million private placement earmarked for the pulmonary pipeline underscores investor confidence in the commercial potential of targeted, patient‑centric therapies.

From a scientific perspective, rapamycin’s role as an mTOR pathway modulator has been well‑documented in oncology and transplant medicine, but its inhaled delivery opens new therapeutic windows for localized disease control with reduced systemic exposure. Early‑stage data suggest LAM‑001 can achieve meaningful lung tissue concentrations while minimizing side effects, a critical factor for chronic rare disease management. If clinical trials confirm efficacy, Quince could secure a first‑to‑market advantage, command premium pricing, and attract orphan‑drug incentives that further improve the financial outlook.

The deal also reflects broader trends in biotech M&A, where larger firms acquire specialized platforms to diversify pipelines and accelerate time‑to‑market. Cooley LLP’s involvement across multiple legal domains highlights the complexity of modern biotech transactions, from IP protection to cyber‑privacy compliance. As Quince scales its rare‑disease franchise, the acquisition positions it to leverage synergies in R&D, regulatory strategy, and commercial rollout, potentially reshaping the competitive landscape for pulmonary therapeutics.

Deal Summary

Quince Therapeutics announced the acquisition of Orphai Therapeutics, a clinical‑stage biotech focused on rare pulmonary diseases. The deal brings Orphai’s lead inhaled rapamycin program LAM‑001 into Quince’s pipeline. The transaction was disclosed on May 18, 2026, with Cooley advising Orphai.